JP2024516645A5 - - Google Patents

Info

Publication number
JP2024516645A5
JP2024516645A5 JP2023565839A JP2023565839A JP2024516645A5 JP 2024516645 A5 JP2024516645 A5 JP 2024516645A5 JP 2023565839 A JP2023565839 A JP 2023565839A JP 2023565839 A JP2023565839 A JP 2023565839A JP 2024516645 A5 JP2024516645 A5 JP 2024516645A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
region
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516645A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026175 external-priority patent/WO2022232044A2/en
Publication of JP2024516645A publication Critical patent/JP2024516645A/ja
Publication of JP2024516645A5 publication Critical patent/JP2024516645A5/ja
Pending legal-status Critical Current

Links

JP2023565839A 2021-04-26 2022-04-25 抗clec12a抗体及びその使用 Pending JP2024516645A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163179755P 2021-04-26 2021-04-26
US63/179,755 2021-04-26
PCT/US2022/026175 WO2022232044A2 (en) 2021-04-26 2022-04-25 Anti-clec12a antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024516645A JP2024516645A (ja) 2024-04-16
JP2024516645A5 true JP2024516645A5 (cg-RX-API-DMAC7.html) 2025-05-01

Family

ID=81648460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565839A Pending JP2024516645A (ja) 2021-04-26 2022-04-25 抗clec12a抗体及びその使用

Country Status (18)

Country Link
US (1) US12600784B2 (cg-RX-API-DMAC7.html)
EP (1) EP4330284A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024516645A (cg-RX-API-DMAC7.html)
KR (1) KR20240004286A (cg-RX-API-DMAC7.html)
CN (1) CN117545774A (cg-RX-API-DMAC7.html)
AR (1) AR125451A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022266584A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020365A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216770A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023003177A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023014316A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP23088759A (cg-RX-API-DMAC7.html)
IL (1) IL307939A (cg-RX-API-DMAC7.html)
MX (1) MX2023011710A (cg-RX-API-DMAC7.html)
PE (1) PE20241789A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023552669A1 (cg-RX-API-DMAC7.html)
TW (1) TW202309084A (cg-RX-API-DMAC7.html)
WO (1) WO2022232044A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022266583A1 (en) 2021-04-26 2023-10-19 Millennium Pharmaceuticals, Inc. Anti-adgre2 antibodies and uses thereof
JP2024514974A (ja) 2021-04-26 2024-04-03 メモリアル スローン-ケタリング キャンサー センター Adgre2及び/またはclec12aを標的とするキメラ受容体及びその使用
WO2024254778A1 (en) * 2023-06-14 2024-12-19 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against cll1 and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
HK1008049A1 (en) 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
ATE110108T1 (de) 1987-12-11 1994-09-15 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
ATE547080T1 (de) 2000-08-30 2012-03-15 Univ Johns Hopkins Vorrichtungen zur intraokularen arzneimittelabgabe
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
JP4383168B2 (ja) 2001-09-12 2009-12-16 ベクトン・ディキンソン・アンド・カンパニー マイクロ針投与デバイスおよび薬物投与デバイス
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
WO2004073551A2 (en) 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
CA2693771A1 (en) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
EP2622074B1 (en) 2010-09-30 2014-11-12 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
MA40579A (fr) * 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
TW201718647A (zh) * 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
MX2020002880A (es) 2017-09-14 2020-10-01 Dragonfly Therapeutics Inc Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1).
WO2019108065A1 (en) * 2017-12-01 2019-06-06 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
US11951129B2 (en) * 2018-01-09 2024-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compositions and methods for targeting CLEC12A-expressing cancers
AU2019414968A1 (en) * 2018-12-27 2021-08-12 Gigagen, Inc. Anti-PD-1 binding proteins and methods of use thereof
KR20220004751A (ko) * 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
AU2022266583A1 (en) 2021-04-26 2023-10-19 Millennium Pharmaceuticals, Inc. Anti-adgre2 antibodies and uses thereof
JP2024514974A (ja) * 2021-04-26 2024-04-03 メモリアル スローン-ケタリング キャンサー センター Adgre2及び/またはclec12aを標的とするキメラ受容体及びその使用

Similar Documents

Publication Publication Date Title
JP2024518776A5 (cg-RX-API-DMAC7.html)
JP2024109678A5 (cg-RX-API-DMAC7.html)
JP2024504384A5 (cg-RX-API-DMAC7.html)
JP2023002562A5 (cg-RX-API-DMAC7.html)
JP2023509448A5 (cg-RX-API-DMAC7.html)
JP2023540526A5 (cg-RX-API-DMAC7.html)
JP2025067915A5 (cg-RX-API-DMAC7.html)
RU2020130795A (ru) Нейтрализующие антитела к env вич-1 и их применение
JP2020501598A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2023525695A5 (cg-RX-API-DMAC7.html)
IL280487B2 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
JP2020522280A5 (cg-RX-API-DMAC7.html)
JP2023509373A5 (cg-RX-API-DMAC7.html)
JP2025508066A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2023542209A5 (cg-RX-API-DMAC7.html)
JP2023510982A5 (cg-RX-API-DMAC7.html)
JP2021512652A5 (cg-RX-API-DMAC7.html)
JP2023506834A5 (cg-RX-API-DMAC7.html)
JP2023524092A5 (cg-RX-API-DMAC7.html)
JP2022500455A5 (cg-RX-API-DMAC7.html)
JP2023552852A5 (cg-RX-API-DMAC7.html)
CN111712521A (zh) Cd38蛋白抗体及其应用
JP2023528416A5 (cg-RX-API-DMAC7.html)